|View printer-friendly version|
Cidara Therapeutics to Present at Two Upcoming Investor Conferences
Cantor Global Healthcare Conference, New York, October 1, 2018at 9:30 a.m. EDT( 6:30 a.m. PDT)
- Ladenburg Thalmann 2018 Healthcare Conference,
New York, October 2, 2018at 8:30 a.m. EDT( 5:30 a.m. PDT)
A live audio webcast and replay of each presentation will be available in the Investors section on the company’s website at www.cidara.com.
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, rezafungin acetate, formerly known as CD101 IV, through clinical trials. Rezafungin has improved pharmacokinetics compared to existing echinocandins and the potential for expanded utility across patient settings. It is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. The company’s Phase 2 STRIVE clinical trial of rezafungin met its primary safety and efficacy objectives, and provides support for Cidara to initiate Phase 3 pivotal trials in the treatment of candidemia and invasive candidiasis and the prophylaxis of invasive fungal infections. Cidara also is leveraging its novel Cloudbreak™ platform to develop antibody-drug conjugates for the treatment of viral and multi-drug resistant Gram-negative bacterial infections. Cloudbreak is the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, our ability to advance our pipeline to deliver novel anti-infectives to patients and providers, the potential for the expanded utility of rezafungin across patient settings, and Cidara’s ability to successfully complete development of rezafungin and receive regulatory approval for any indication. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in
Westwicke Partners, LLC
Sam Brown Inc.
Source: Cidara Therapeutics, Inc.